All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1100+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Iterum Therapeutics nabs FDA approval for oral UTI med Orlynvah
Small molecule, urinary tract infection - Read more

Boston Scientific, Medtronic’s heart failure algo gets UK NICE recommendation
Medical device, heart failure, algorithm - Read more

THE GOOD
Business Development

Shenyang Sunshine (3SBio subsidiary) buys Mainland China, Hong Kong future commercialization rights for RMX Biopharma’s (Haihe Biopharma subsidiary) oral Paclitaxel solution
Small molecule, cancer - Read more

THE GOOD
Clinical Trials

Tyra Biosciences posts “encouraging” Ph1/2 results for urothelial carcinoma hopefull TYRA-300, though some adverse events reported
Small molecule, urothelial carcinoma - Read more

Eli Lilly’s Ebglyss demonstrates “meaningful improvements” in skin clearance, itching relief (cause by atopic dermatitis) in Ph3b data
Monoclonal antibody, atopic dermatitis - Read more

Dermavant Biosciences presents Ph3 data for atopic dermatitis topical Vtama
Small molecule, atopic dermatitis - Read more

Johnson & Johnson posts Ph3b data for Tremfya in treating "overlooked and undertreated" sub-population in plaque psoriasis
Monoclonal antibody, plaque psoriasis - Read more

Leo Pharma presents final Ph3 results for Adbry in adults & adolescents with atopic dermatitis
Monoclonal antibody, atopic dermatitis - Read more

Bristol Myers Squibb, Ideaya Bioscience post positive interim Ph1 data for IDE397 small molecule in urothelial, lung cancer
Small molecule, urothelial cancer, lung cancer - Read more

Revolution Medicines presents “encouraging” initial Ph1/1b data for RMC-9805 in pancreatic ductal adenocarcinoma
Small molecule, pancreatic ductal adenocarcinoma, cancer - Read more

Spur Therapeutics touts positive Ph1/2 data for Gaucher disease gene therapy hopeful FLT201
Gene therapy, Gaucher disease, AAV - Read more

THE GOOD
Company Launches

Dash Bio launches with $6.5M Seed raise, “technology-first approach“ to drug development services, technologies
Drug development, bioanalysis, AI, robotics - Read more

THE GOOD
Earning & Finances

Sanofi rockets past Q3 expectations thanks to surging Beyfortus sales
Monoclonal antibody, respiratory syncytial virus, vaccine - Read more

PRESENTED BY YOU?
Get the attention of 1100+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here! Check out our prospectus for more details.

And if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Jade Biosciences undisclosed financing extension to $95M total, looking to “redefine” the standard of care for autoimmune diseases
Undisclosed modality, autoimmune - Read more

Agomab Therapeutics $89M Series D, pushing forward “tissue-specific” fibrotic disease approach
Small molecule, fibrostenosing Crohn's disease, pulmonary fibrosis, liver fibrosis - Read more

enGene $60M private placement, advancing bladder cancer gene therapy detalimogene
Gene therapy, bladder cancer - Read more

Molecular Partners $20M underwritten offering, Radio-DARPin therapeutics
Radiopharma, oncology, cancer - Read more

THE GOOD
Investments

GSK earmarks $800M for PA, USA facility expansion, 200 jobs
Manufacturing, sterile liquids, drug substance, R&D pilot plant - Read more

THE GOOD
IPO

Septerna IPO a smashing success, raises $288M
Small molecule, hypoparathyroidism - Read more

THE GOOD
Mergers & Acquisitions

Ledger Run acquires Assentia, clinical trial agreement negotiation tech
Clinical trial contract negotiation, functional service provider - Read more

THE GOOD
Partnerships

AbbVie, Gedeon Richter announce new discovery, development pact focued on neuropsychiatry
Small molecule, neuropsychiatric disorder, drug discovery, drug development - Read more

Coeptis Therapeutics, Deverra Therapeutics expand field of use for allogeneic NK cell therapy technology
Cell therapy, viral infections, pandemic preparedness, NK cell - Read more

Genprex, The University of Michigan Rogel Cancer Center sign Sponsored Research Agreement to study gene used in Reqorsa cancer gene therapy
Gene therapy, translocated lung cancer - Read more

THE GOOD
Politics & Policy

US House Republicans demand increased transparency from government-funded clinical trials
Clinical trials, taxpayer funding - Read more [Paywall]

THE GOOD
Research

Tessera touts further preclinical data for in vivo gene editing tech
Gene editing, alpha-1 antitrypsin deficiency, sickle cell disease - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Company Shutdown

Elucida Oncology closes doors due to “lack of funding”
Antibody-drug conjugate, cancer - Read more [Paywall]

THE BAD
Earnings & Finances

GenSight Biologics running on fumes as cash supples are “weeks away” from depletion
Gene therapy, Leber hereditary optic neuropathy, eye disease - Read more

THE UGLY
Criminal Acts

BeiGene senior executive under investigation in China, “not related to BeiGene’s activities” according to company
Smuggling - Read more

THE UGLY
Patient Access

UK’s MHRA has to remind people that GLP-1s aren’t for “Instagram” or cosmetic use
GLP-1, obesity, diabetes - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here